Tenaya therapeutics reports second quarter 2023 financial results and provides business update

Dosing of first patient in phase 1b trial of tn-201 on track to occur in q3 2023 data from phase 1 clinical trial of tn-301 accepted for presentation at hfsa 2023 ind application for tn-401 anticipated in second half 2023 second quarter cash and investments of $152 million; runway to fund operations into first half 2025 south san francisco, calif., aug. 09, 2023 (globe newswire) -- tenaya therapeutics, inc. (nasdaq: tnya), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the second quarter ended june 30, 2023.
TNYA Ratings Summary
TNYA Quant Ranking